References
- Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401(6750):282–286.
- Douglas SA, Tayara L, Ohlstein EH, et al. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2002;359(9322):1990–1997.
- Langham RG, Kelly DJ, Gow RM, et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis. 2004;44(5):826–831.
- Bousette N, Giai A. Urotensin-II and cardiovascular diseases. Curr Hypertens Rep. 2006;8(6):479–483.
- Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol. 2002;135(1):25–27.
- Douglas SA, Sulpizio AC, Piercy V, et al. Differential vasoconstrictive activity of human urotensin II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 2000;131(7):1262–1274.
- Ng LL, Loke I, O'Brien R, et al. Plasma urotensin in human systolic heart failure. Circulation. 2002;106(23):2877–2880.
- Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res. 2003;93(3):246–253.
- Loirand G, Rolli-Derkinderen M, Pacaud P. Urotensin II and atherosclerosis. Peptides. 2008;29(5):778–782.
- Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens. 2001;19(12):2185–2190.
- Brkovic A, Hattenberger A, Kostenis E, et al. Functional and binding characterizations of urotensin II related peptides in human and rat urotensin II-receptor. J Pharmacol Exp Ther. 2003;306(3):1200–1209.
- Cosenzi A. Non peptidic urotensin II antagonists: perspectives for a new class of drugs. Cardiovasc Hematol Agents Med Chem. 2008;6(2):80–91.
- Bousette N, Hu F, Ohlstein EH, et al. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol. 2006;41(2):285–295.
- Portnoy A, Kumar S, Behm DJ, et al. Effects of urotensin II receptor antagonist, GSK1440115, in asthma. Front Pharmacol. 2013;4:54.
- Douglas SA, Behm DJ, Aiyar NV, et al. Nonpeptide urotensin II receptor antagonist I: in vitro pharmacological characteristics of SB-706375. Br J Pharmacol. 2005;145(5):620–635.
- Lawson EC, Luci DK, Ghosh S, et al. Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. J Med Chem. 2009;52(23):7432–7445.
- Lim CJ, Woo SE, Ko SI, et al. Benzo[b]thiophene-2-carboxamide derivatives as potent urotensin-II receptor antagonists. Bioorg Med Chem Lett. 2016;26(19):4684–4686.
- Oh KS, Lee JH, Yi KY, et al. A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure. Eur J Pharmacol. 2017;799:94–102.
- Clozel M, Binkert C, Birker-Robaczewska M, et al. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362: 1-[2-(4-benzyl-4- hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther. 2004;311(1):204–212.
- Nishi M, Yonesu K, Tagawa H, et al. A novel and highly potent urotensin II receptor antagonist inhibits urotensin II-Induced pressure response in mice. J Cardiovasc Pharmacol. 2019;73(1):15–21.
- Tandon R, Soni A, Singh RK, et al. Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice. Eur J Pharmacol. 2020;886:173391.
- Marumoto S, Kiho T, Matsui S, et al. WO Patent (2010) Urotensin-ii receptor antagonists. WO2010087399A1 WIPO (PCT). 2010.
- Nishi M, Tagawa H, Ueno M, et al. The urotensin II receptor antagonist DS37001789 ameliorates mortality in pressure-overload mice with heart failure. Heliyon. 2020;6(2):e03352–e033510.